DRI Healthcare Trust has announced that the U.S. Food and Drug Administration (FDA) has granted approval for Ekterly® (sebetralstat), developed by KalVista Pharmaceuticals, as the first and only oral on-demand therapy for treating acute attacks of hereditary angioedema $(HAE)$ in patients aged 12 years and older. This approval marks a significant advancement for those suffering from this rare genetic disorder characterized by severe swelling. As part of a financial arrangement, DRI Healthcare is entitled to a tiered royalty on the worldwide net sales of Ekterly. Additionally, KalVista has opted to receive further funding, increasing DRI Healthcare's total investment to $127 million, enhancing the financial collaboration between the two organizations.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。